Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more
Market Cap & Net Worth: Hainan Honz Pharmaceutical Co (300086)
Hainan Honz Pharmaceutical Co (SHE:300086) has a market capitalization of $541.52 Million (CN¥3.97 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #11772 globally and #2830 in its home market, demonstrating a -2.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Honz Pharmaceutical Co's stock price CN¥8.73 by its total outstanding shares 455124411 (455.12 Million).
Hainan Honz Pharmaceutical Co Market Cap History: 2015 to 2026
Hainan Honz Pharmaceutical Co's market capitalization history from 2015 to 2026. Data shows change from $1.06 Billion to $541.52 Million (-5.09% CAGR).
Hainan Honz Pharmaceutical Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Honz Pharmaceutical Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.64x
Hainan Honz Pharmaceutical Co's market cap is 0.64 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.06 Billion | $409.76 Million | $68.31 Million | 2.59x | 15.55x |
| 2016 | $840.26 Million | $471.47 Million | $46.16 Million | 1.78x | 18.20x |
| 2017 | $651.92 Million | $480.83 Million | $50.20 Million | 1.36x | 12.99x |
| 2018 | $362.18 Million | $882.74 Million | $13.37 Million | 0.41x | 27.10x |
| 2019 | $325.13 Million | $1.01 Billion | -$26.46 Million | 0.32x | N/A |
| 2020 | $347.38 Million | $921.64 Million | $9.34 Million | 0.38x | 37.20x |
| 2021 | $538.41 Million | $836.57 Million | $10.99 Million | 0.64x | 49.00x |
| 2022 | $385.82 Million | $535.75 Million | -$187.58 Million | 0.72x | N/A |
| 2023 | $364.11 Million | $739.57 Million | $11.53 Million | 0.49x | 31.58x |
| 2024 | $303.94 Million | $472.82 Million | -$216.21 Million | 0.64x | N/A |
Competitor Companies of 300086 by Market Capitalization
Companies near Hainan Honz Pharmaceutical Co in the global market cap rankings as of March 18, 2026.
Key companies related to Hainan Honz Pharmaceutical Co by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hainan Honz Pharmaceutical Co Historical Marketcap From 2015 to 2026
Between 2015 and today, Hainan Honz Pharmaceutical Co's market cap moved from $1.06 Billion to $ 541.52 Million, with a yearly change of -5.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥541.52 Million | -27.43% |
| 2025 | CN¥746.21 Million | +145.51% |
| 2024 | CN¥303.94 Million | -16.52% |
| 2023 | CN¥364.11 Million | -5.63% |
| 2022 | CN¥385.82 Million | -28.34% |
| 2021 | CN¥538.41 Million | +54.99% |
| 2020 | CN¥347.38 Million | +6.85% |
| 2019 | CN¥325.13 Million | -10.23% |
| 2018 | CN¥362.18 Million | -44.44% |
| 2017 | CN¥651.92 Million | -22.41% |
| 2016 | CN¥840.26 Million | -20.91% |
| 2015 | CN¥1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hainan Honz Pharmaceutical Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $541.52 Million USD |
| MoneyControl | $541.52 Million USD |
| MarketWatch | $541.52 Million USD |
| marketcap.company | $541.52 Million USD |
| Reuters | $541.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.